Zobrazeno 1 - 10
of 264
pro vyhledávání: '"M. Ian Phillips"'
Autor:
Andrew B Burns, Corinna Doris, Kevin Vehar, Vinit Saxena, Cameron Bardliving, Parviz A Shamlou, M Ian Phillips
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0252575 (2021)
Bone marrow derived human Mesenchymal Stem Cells (hMSCs) are an attractive candidate for regenerative medicine. However, their harvest can be invasive, painful, and expensive, making it difficult to supply the enormous amount of pure hMSCs needed for
Externí odkaz:
https://doaj.org/article/1f5fd361eddf44a0a47410ab39d150ec
This text introduces underlying principles of the endocrine regulation of behavior in animals and humans. Every chapter begins by stating a principle, followed by specific examples of hormone actions derived from scientific experiments and clinical o
Autor:
Cameron Bardliving, Kevin Vehar, Corinna Doris, Andrew B. Burns, M. Ian Phillips, Saxena Vinit, Parviz Shamlou
Publikováno v:
PLoS ONE
PLoS ONE, Vol 16, Iss 6, p e0252575 (2021)
PLoS ONE, Vol 16, Iss 6, p e0252575 (2021)
Bone marrow derived human Mesenchymal Stem Cells (hMSCs) are an attractive candidate for regenerative medicine. However, their harvest can be invasive, painful, and expensive, making it difficult to supply the enormous amount of pure hMSCs needed for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e66e19a5ac846ddbad490a5a3c2edb5d
http://europepmc.org/articles/PMC8208585
http://europepmc.org/articles/PMC8208585
Autor:
Lijuan Chen, M Ian Phillips, Hui-Lai Miao, Rong Zeng, Gangjian Qin, Il-man Kim, Neal L Weintraub, Yaoliang Tang
Publikováno v:
PLoS ONE, Vol 9, Iss 10, p e107841 (2014)
Stem cell therapy has a potential for regenerating damaged myocardium. However, a key obstacle to cell therapy's success is the loss of engrafted cells due to apoptosis or necrosis in the ischemic myocardium. While many strategies have been developed
Externí odkaz:
https://doaj.org/article/11baa29f74184219a44b26b12e8c501b
Publikováno v:
Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual)
Universidade de São Paulo (USP)
instacron:USP
Universidade de São Paulo (USP)
instacron:USP
Exercise training (ET) has been established as an important treatment for obesity, since it counteracts aberrant cardiac metabolism and weight gain; however, underlying mechanisms remain to be further determined. MicroRNAs (miRNAs) inhibit protein ex
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eef1a912a0d42984aa9d19c04b08bfc6
https://pubmed.ncbi.nlm.nih.gov/29746886
https://pubmed.ncbi.nlm.nih.gov/29746886
Autor:
M. Ian Phillips, Andrew B. Burns
Publikováno v:
Expert Opinion on Orphan Drugs. 2:1197-1209
Introduction: Gene therapy is emerging from a checkered past to success in several diseases, most of them are rare. Currently, the goal of most gene therapy trials is gene replacement, gene correction or knockdown of gene products for monogenetic dis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a00e94e0d4ee926b8b8a80f19f7c7c7b
https://doi.org/10.1517/21678707.2014.978284
https://doi.org/10.1517/21678707.2014.978284
Autor:
M. Ian Phillips, Jongserk Robert Lee
Publikováno v:
Expert Opinion on Orphan Drugs. 2:759-763
Although the pipeline for new drugs seemed to be drying up, the number of new ‘first-in-class’ drugs appeared to be increasing. First-in-class drugs are those which use a new and unique mechanism for treating a disease or medical condition. They
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::202a1b211a7fdde6fcc08accfd72a97a
https://doi.org/10.1517/21678707.2014.931806
https://doi.org/10.1517/21678707.2014.931806
Publikováno v:
Expert Opinion on Orphan Drugs. 1:675-679
The Food and Drug Administration (FDA) data show that there are a growing number of applications and approvals for orphan drugs every year. Newer orphan drugs are generally sold at high prices, which has raised the question about the sustainability o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a1c7a5a236d995378f84f80a2782a893
https://doi.org/10.1517/21678707.2013.829401
https://doi.org/10.1517/21678707.2013.829401
Autor:
M. Ian Phillips
Publikováno v:
Clinical Pharmacology & Therapeutics. 92:182-192
There are an estimated 7,000 “orphan diseases,” but treatments are currently available for only about 5% of them. Recent progress in the advanced platforms of gene therapy, stem cell therapy, gene modification, and gene correction offers possibil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::613d9bdcf16d5837e7d787196d601d17
https://doi.org/10.1038/clpt.2012.82
https://doi.org/10.1038/clpt.2012.82
Autor:
Menfo A. Imoisili, Chandana Thorat, M. Ian Phillips, Scott N. Freeman, Kui Xu, Francesca Joseph, Renan Bonnel
Publikováno v:
Pediatrics. 129:516-521
OBJECTIVES: The 1983 US Orphan Drug Act (ODA) provided incentives to stimulate treatment product development for patients with rare disease. This article highlights a decade of ODA contributions to this goal for children with RDs. METHODS: An interna
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e32cd17d4c88422972ae2a5f38597bfa
https://doi.org/10.1542/peds.2011-1798
https://doi.org/10.1542/peds.2011-1798